Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options DOI Open Access
Eguzkiñe Díez-Martín, Leidi Hernández-Suárez, Carmen Muñoz‐Villafranca

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7062 - 7062

Published: June 27, 2024

In inflammatory bowel diseases (IBDs), such as Crohn's disease (CD) and ulcerative colitis (UC), the immune system relentlessly attacks intestinal cells, causing recurrent tissue damage over lifetime of patients. The etiology IBD is complex multifactorial, involving environmental, microbiota, genetic, immunological factors that alter molecular basis organism. Among these, microbiota cells play pivotal roles; generates antigens recognized by antibodies, while autoantibodies target attack membrane, exacerbating inflammation damage. Given altered framework, analysis multiple biomarkers in patients proves exceedingly valuable for diagnosing prognosing IBD, including markers like C reactive protein fecal calprotectin. Upon detection classification patients, specific treatments are administered, ranging from conventional drugs to new biological therapies, antibodies neutralize molecules tumor necrosis factor (TNF) integrin. This review delves into targets, biomarkers, treatment options, monitoring techniques, and, ultimately, current challenges management.

Language: Английский

Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review DOI Open Access

Min’an Zhao,

Jiayi Chu,

Shiyao Feng

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 164, P. 114985 - 114985

Published: June 11, 2023

The gut microbiota is indispensable for maintaining host health by enhancing the host's digestive capacity, safeguarding intestinal epithelial barrier, and preventing pathogen invasion. Additionally, exhibits a bidirectional interaction with immune system promotes of to mature. Dysbiosis microbiota, primarily caused factors such as genetic susceptibility, age, BMI, diet, drug abuse, significant contributor inflammatory diseases. However, mechanisms underlying diseases resulting from dysbiosis lack systematic categorization. In this study, we summarize normal physiological functions symbiotic in healthy state demonstrate that when occurs due various external factors, are lost, leading pathological damage lining, metabolic disorders, barrier damage. This, turn, triggers disorders eventually causes systems. These discoveries provide fresh perspectives on how diagnose treat unrecognized variables might affect link between illnesses need further studies extensive basic clinical research will still be required investigate relationship future.

Language: Английский

Citations

149

Flavonoids: structure–function and mechanisms of action and opportunities for drug development DOI
Stephen Safe, Arul Jayaraman, Robert S. Chapkin

et al.

Toxicological Research, Journal Year: 2021, Volume and Issue: 37(2), P. 147 - 162

Published: Jan. 20, 2021

Language: Английский

Citations

122

AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review DOI Open Access
Jana G. Hashash,

Jaclyn R. Elkins,

James D. Lewis

et al.

Gastroenterology, Journal Year: 2024, Volume and Issue: 166(3), P. 521 - 532

Published: Jan. 23, 2024

Language: Английский

Citations

112

Dietary management of adults with IBD — the emerging role of dietary therapy DOI
Jessica A. Fitzpatrick, Sarah L. Melton, Chu K Yao

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2022, Volume and Issue: 19(10), P. 652 - 669

Published: May 16, 2022

Language: Английский

Citations

91

Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts DOI Creative Commons
Timon E. Adolph, Jingwan Zhang

Gut, Journal Year: 2022, Volume and Issue: 71(12), P. 2574 - 2586

Published: Sept. 16, 2022

The diet and gut microbiota have been extensively interrogated as a fuel for inflammation in inflammatory bowel diseases (IBDs) the last few years. Here, we review how specific nutrients, typically enriched Western diet, instigate or deteriorate experimental genetically susceptible host discuss microbiota-dependent independent mechanisms. We depict study landscape of nutritional trials paediatric adult IBD delineate common grounds dietary advice. Conclusively, reflects critical rheostat microbial dysbiosis IBD. Dietary restriction by exclusive enteral nutrition, with without exclusion is effectively treating Crohn’s disease, while are less conclusive. Insights into molecular mechanisms therapy will change perception allow us to enter era precision nutrition. To achieve this, need carefully designed scientific rigour comparable medical trials, which also requires action from stake holders. Establishing evidence-based does not only hold promise avoid long-term immunosuppression, but provide widely accessible at low cost. Identification culprits disturbing health bears potential prevent allows informed decision making food politics.

Language: Английский

Citations

82

The Role of Diet and Gut Microbiota in Regulating Gastrointestinal and Inflammatory Disease DOI Creative Commons
Paul A. Gill, S Inniss, Tomoko Kumagai

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: April 5, 2022

Diet is an important lifestyle factor that known to contribute in the development of human disease. It well established poor diet plays active role exacerbating metabolic diseases, such as obesity, diabetes and hypertension. Our understanding how immune system drives chronic inflammation disease pathogenesis has evolved recent years. However, contribution dietary factors inflammatory conditions bowel disease, multiple sclerosis arthritis remain poorly defined. A western been associated pro-inflammatory, contrast traditional patterns are being anti-inflammatory. This may be due direct effects nutrients on cell function. also affect composition function gut microbiota, which consequently affects immunity. In animal models modulate gastrointestinal tract other peripheral sites. Despite limitations models, there now emerging evidence show anti-inflammatory translate diseases. appropriately designed, larger clinical studies must conducted confirm therapeutic benefit therapy.

Language: Английский

Citations

80

IL-10 constrains sphingolipid metabolism to limit inflammation DOI Creative Commons
Autumn G. York, Mathias Skadow, Joonseok Oh

et al.

Nature, Journal Year: 2024, Volume and Issue: 627(8004), P. 628 - 635

Published: Feb. 21, 2024

Interleukin-10 (IL-10) is a key anti-inflammatory cytokine that can limit immune cell activation and production in innate types

Language: Английский

Citations

79

Gut Microbiota in Psoriasis DOI Open Access

Mihaela Cristina Buhaș,

Laura Ioana Gavrilaș, Rareș Candrea

et al.

Nutrients, Journal Year: 2022, Volume and Issue: 14(14), P. 2970 - 2970

Published: July 20, 2022

Psoriasis is a chronic inflammatory skin disease with autoimmune pathogenic characteristics and caused by inflammation, which results in uncontrolled keratinocyte growth defective differentiation. The link between the gut microbiota immune system regulation opened novel angle to understand pathogenesis of many multifactorial diseases, including psoriasis. Current evidence suggests that modulation microbiota, both through dietary approaches supplementation probiotics prebiotics, could represent therapeutic approach. present work aims highlight latest scientific regarding microbiome alterations psoriatic patients, as well state art insights terms microbiome-targeted therapies promising preventive tools for

Language: Английский

Citations

78

Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems DOI

Hicheme Hadji,

Kawthar Bouchemal

Advanced Drug Delivery Reviews, Journal Year: 2022, Volume and Issue: 181, P. 114101 - 114101

Published: Jan. 6, 2022

Language: Английский

Citations

73

Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome DOI Open Access
Brian Bicknell, Ann Liebert, Thomas J. Borody

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(11), P. 9577 - 9577

Published: May 31, 2023

The human gut microbiome contains the largest number of bacteria in body and has potential to greatly influence metabolism, not only locally but also systemically. There is an established link between a healthy, balanced, diverse overall health. When becomes unbalanced (dysbiosis) through dietary changes, medication use, lifestyle choices, environmental factors, ageing, this profound effect on our health linked many diseases, including metabolic inflammatory neurological diseases. While humans largely association dysbiosis with disease, animal models, causative can be demonstrated. brain particularly important maintaining health, strong neurodegenerative neurodevelopmental This suggests that microbiota composition used make early diagnosis diseases modifying microbiome-gut-brain axis might present therapeutic target for have proved intractable, aim altering trajectory such as Alzheimer's Parkinson's multiple sclerosis, autism spectrum disorder, attention-deficit hyperactivity among others. other potentially reversible migraine, post-operative cognitive dysfunction, long COVID, which considered models therapy disease. role traditional methods microbiome, well newer, more novel treatments faecal transplants photobiomodulation, are discussed.

Language: Английский

Citations

71